Parkinsonian DisordersInorganic ChemicalsSupranuclear Palsy, ProgressiveMultiple System AtrophyParkinson DiseasePsychotic DisordersPsychoses, Substance-InducedLevodopaParkinson Disease, SecondaryAntiparkinson AgentsSchizophreniaBipolar Disorder1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAffective Disorders, PsychoticGlobus PallidusHypokinesiaMuscle RigidityBrain ChemistrySubthalamic NucleusDyskinesia, Drug-InducedBrainProdromal SymptomsMental DisordersSchizophrenic PsychologyBrain InjuriesDyskinesiasPsychiatric Status Rating ScalesBrain MappingOxidopamineSubstantia NigraExtrapyramidal TractsCorpus StriatumDelusionsBrain NeoplasmsMood DisordersDopamineTremorEarly Medical InterventionDeep Brain StimulationParanoid DisordersBasal GangliaHallucinationsAnxiety DisordersAntipsychotic AgentsMagnetic Resonance ImagingDiagnostic and Statistical Manual of Mental DisordersCarbidopaDopamine AgentsMovement DisordersSchizotypal Personality DisorderCognition DisordersNeuronsOlivopontocerebellar AtrophiesNeuropsychological TestsBenserazideMazindolDisease Models, Animal